Data integrity: the keystone for AI adoption, patient safety and organisational reputation
pharmafile | August 9, 2026 | Feature | Manufacturing and Production |Â Â Devices, data quality, digital technologies, regulatory practiceÂ
By Gurdip Singh
Artificial intelligence is rapidly moving from future aspiration to operational reality across the pharmaceutical and medical device sectors. From accelerating regulatory workflows to managing increasingly complex labelling and multilingual content, AI promises to help organisations cope with growing operational pressures while improving efficiency and reducing costs.
Yet amid the excitement surrounding the technology, one critical issue risks being overlooked. The success of AI will depend far less on the sophistication of the algorithms than on the quality of the data that underpins them.
This is particularly significant for highly regulated industries. Pharmaceutical manufacturers are facing an increasingly demanding regulatory landscape, with major legislative changes across Europe and the United States, expanding product portfolios and mounting pressure to bring medicines to market more quickly. At the same time, many organisations continue to experience shortages of experienced regulatory and quality professionals, leaving already stretched teams responsible for managing increasingly complex product information.
Against this backdrop, AI appears to offer an attractive solution. Automation has the potential to streamline repetitive processes, accelerate document preparation, support multilingual content management and reduce the administrative burden placed upon regulatory teams. It is easy to understand why many organisations are eager to explore what the technology can deliver.
However, there is a risk that the urgency to embrace AI leads organisations to overlook the foundations required for successful implementation.
Across many sectors, businesses continue to rely on fragmented legacy systems, duplicated information and disconnected repositories that have evolved over many years. Applying sophisticated AI tools to these environments does not eliminate those weaknesses. Instead, it risks amplifying them.
Industry research already reflects this challenge. A recent NVIDIA [1] enterprise study found that 48% of business leaders identified data-related issues as the single greatest barrier to successful AI implementation. Gartner [2] has also reported that poor data quality [3] continues to undermine AI initiatives, with fewer than one-third delivering the return on investment organisations expected.
For pharmaceutical companies, the consequences extend well beyond operational inefficiency.
In regulated environments, every product label, patient information leaflet, instructions for use and regulatory submission depends upon accurate, validated and consistent information. AI systems are only as reliable as the data they are asked to process. Where that information is incomplete, duplicated or poorly governed, the potential exists for small inaccuracies to become significant compliance risks.
Something as simple as introducing an incorrect regional date format, using outdated approved wording or inadvertently changing a mandatory formatting requirement may appear relatively minor. Within pharmaceutical manufacturing, however, such discrepancies can interrupt regulatory workflows, delay product launches, trigger costly investigations or, in the worst cases, contribute to product recalls. Ultimately, failures in information governance have implications that extend beyond compliance to patient safety and organisational reputation.
Rather than viewing this as a reason to slow AI adoption, it should be regarded as an opportunity to establish stronger information management practices.
A trusted, structured and well-governed data foundation enables organisations to unlock the full value of automation while maintaining confidence in the integrity of regulated content. Once that foundation is in place, AI can support faster document creation, more efficient multilingual updates, improved change management and greater consistency across global product portfolios.
Importantly, this is not simply a technology challenge. It is a governance challenge.
Successful AI deployment depends upon establishing a single source of trusted information that allows automated systems to operate within validated, controlled environments. Without that foundation, even the most advanced AI solutions will struggle to deliver reliable outcomes. With it, organisations are far better positioned to improve efficiency while maintaining compliance with increasingly demanding regulatory requirements.
As investment in AI continues to accelerate, organisations should resist the temptation to judge success by the speed of implementation alone. Competitive advantage is more likely to come from combining advanced technology with robust information governance than from adopting the latest AI platform before the necessary foundations have been established.
The conversation around AI often focuses on what the technology will eventually achieve. Equally important is ensuring that the information supporting those systems is accurate, consistent and trustworthy from the outset. In highly regulated industries, data integrity is not an obstacle to AI adoption. It is the factor that will determine whether AI delivers on its promise.
1. https://blogs.nvidia.com/blog/state-of-ai-report-2026/
3. https://talyx.ai/insights/enterprise-ai-implementation-failure
- Gurdip Singh is CEO of Kallik, a provider of software for safety critical industries and regulated markets, including pharmaceuticals and medical device sectors. Founded in 2001, the firm previously collaborated with Aston University’s College of Engineering and Physical Sciences on a Knowledge Transfer Partnership to incorporate advanced computer vision, AI and machine learning into its solutions
This article featured in: August 2026 – The Pharmafile Brief
Related Content
Functional lung imaging offers new possibilities for respiratory care
Advances in computed tomography (CT) technology are helping to reshape the diagnosis and management of …
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …
